NDA 214993 · Theragnostics
Nephroscan
Technetium Tc-99m Succimer · Intravenous · Lead Chelator
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Feb 18, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Feb 18, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
25
18 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 29, 2024.
NEPHROSCAN, after radiolabeling with technetium Tc 99m, is indicated for use as an aid in the scintigraphic evaluation of renal parenchymal disorders in adult and pediatric patients including term neonates. NEPHROSCAN, after radiolabeling with technetium Tc 99m, is a radioactive diagnostic agent indicated for use as an aid in the scintigraphic evaluation of renal parenchymal disorders in adults and pediatric patients including term neonates. ( 1 )
Mechanism: Technetium Tc 99m succimer binds to the cortical region of kidneys and in conjunction with gamma scintigraphy or single photon emission computed tomography (SPECT) is used to image the renal cortices.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 18, 2022 Original approval · Type 5 - New Formulation or New Manufacturer · priority review OrphanLetterLabelReview
1 products under this application
- NEPHROSCAN · TECHNETIUM TC-99M SUCCIMER N/A · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Succimer" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use7
- hypertension4
- skin striae4
- weight increased4
- cushingoid3
- blood lead increased2
- cough2
- drug ineffective for unapproved indication2
- exposure during pregnancy2
- eye irritation2
- rebound effect2
- abortion spontaneous1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 8 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data.
Shaikh N, Craig JC, Rovers MM, et al. · JAMA Pediatr 2014 · Meta-Analysis, Review
Sponsor: Theragnostics
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.